In brief
Non-specific low back pain is pain located between the costal margin and the gluteal folds, with or without radiation, for which no specific pathological or anatomical cause is identified; this diagnosis of exclusion accounts for 90 to 95 % of low back pain in primary care. The leading cause of disability worldwide, its chronicity is predicted mainly by psychosocial factors (catastrophising, kinesiophobia, depression) and sustained by central sensitisation rather than by a structural lesion. Once red flags have been ruled out, first-line treatment is non-pharmacological: education, advice to stay active, self-management and exercise, with no type of exercise being superior. GBD 2021 estimates that 619 million people were affected in 2020.
Clinical synthesis based on the most recent meta-analyses and pivotal trials: GBD 2021, RESTORE Lancet 2023, the Lancet Series 2018, NICE NG59 and prospective data from 2025-2026.
Clinical summary
- The diagnosis of non-specific low back pain is one of exclusion and accounts for 90-95 % of low back pain cases in primary care.1,9
- It is the leading cause of disability worldwide. GBD 2021 estimates 619 million people affected in 2020, with a projection of 843 million in 2050.2
- The psychosocial factors (catastrophising, kinesiophobia, depression) are the strongest predictors of progression to chronicity.10,11
- Chronicity is sustained by mechanisms of central sensitisation and nociplastic plasticity rather than by a persistent structural lesion.3
- The rate of recurrence within a year is substantial (≈ 33 % at 1 year, up to 73 % depending on the definitions).14
- The initial assessment must systematically rule out red flags (fracture, infection, tumour, cauda equina) before concluding that the low back pain is non-specific.4,5
- Bardin's diagnostic triad: non-specific 90-95 %, radicular 5-10 %, specific pathology < 1 %.6
- Imaging is not indicated routinely without a red flag: it may reveal abnormalities unrelated to the pain and generate a nocebo effect.1,7
- Stratification by risk group (STarT Back Tool) slightly reduced disability, at lower cost, in Hill's 2011 British trial; subsequent trials diverge.8
- The first-line treatment is non-pharmacological: education, advice to stay active, self-management (APTA 2021, NICE NG59).12,15
- Therapeutic exercise is a pivotal intervention, but no type is superior to the others: the choice should follow the patient's preferences.16,17
- The use of manual therapy may bring a short-term benefit in chronic low back pain, on low to very low certainty evidence (Cochrane 2026). It complements the active approach (exercise + education); it does not replace it.18
- The Cognitive Functional Therapy (CFT) approach (RESTORE trial, Lancet 2023) brings a clinically meaningful reduction in pain and disability in disabled chronic patients, with effects maintained at 3 years in the 312 of 492 participants followed up.19,20
- Self-management combining pain neuroscience education (PNE) and exercise is the cornerstone of recurrence prevention.21,22
- Return to sport must be based on functional and psychological criteria, never on a fixed timetable.23
- Serious conditions (leaking aortic aneurysm, pyogenic spondylodiscitis, vertebral metastases) can mimic common low back pain: vigilance must be constant.4,5
- Referral to the doctor if there is a red flag; to a specialist psychologist if yellow flags are marked and persistent.11,15
- The PROMs that are validated (Oswestry Disability Index, NPRS) are essential for objectively measuring progress and for shared decision-making.12
Contents
- What are the fundamentals to know about non-specific low back pain?
- How can non-specific low back pain be assessed and diagnosed with certainty?
- Which treatment strategies are most effective for non-specific low back pain?
- How do you secure lasting recovery and prevent recurrence of non-specific low back pain?
- What do real clinical cases teach us about non-specific low back pain?
- How do you apply these recommendations concretely in your practice?
What are the fundamentals to know about non-specific low back pain?
How is this condition defined, who does it affect and what are the risk factors?
Non-specific low back pain is defined as pain and discomfort localised below the costal margin and above the inferior gluteal folds, with or without referred leg pain, for which no specific pathological or anatomical cause (infection, tumour, osteoporotic fracture, structural deformity, inflammatory disorder, radicular syndrome or cauda equina syndrome) can be identified.¹ This definition by exclusion covers the overwhelming majority of cases in primary care, about 90-95 % according to Bardin's consolidated diagnostic triad (Med J Aust 2017): non-specific 90-95 %, radicular 5-10 %, specific pathology < 1 %.²,⁶
Epidemiologically, low back pain has been the leading cause of years lived with disability worldwide (YLDs) for nearly three decades.¹ The Global Burden of Disease 2021 analysis estimates that 619 million people were living with low back pain in 2020, with a projection of 843 million by 2050 owing to population growth and ageing.² Subsequent estimates (Wu 2020, Ann Transl Med) confirm an age-standardised point prevalence of about 7.5 %, although the absolute number of cases rose from 377.5 M (1990) to 577 M (2017).³ 🌍
📊 Global burden of low back pain: GBD 2021 (Lancet Rheumatol 2023)
Number of people living with low back pain (in millions), 1990 → 2050 projection
Source: GBD 2021 Low Back Pain Collaborators. Lancet Rheumatol. 2023;5(6):e316-e329. PMID 37273833.
Prevalence increases with age, peaking between 50 and 80 years, and is slightly higher in women than in men.²,³ Low back pain affects all population groups (adolescents, working-age adults, older people), with a major socio-economic impact: Hartvigsen et al. already noted in 2018 in the Lancet Low Back Pain Series that low back pain is “manageable with evidence-based interventions, but it remains over-medicalised in most high-income countries”.¹
The risk factors are multifactorial and ranked differently depending on whether initial onset or progression to chronicity is concerned:
- Individual and anthropometric factors : older age, female sex, high body mass index, previous low back pain. Smoking is associated with a pooled OR of 1.30 in the Shiri 2010 meta-analysis (Am J Med).⁴
- Psychosocial factors : the strongest predictors of progression to chronicity and persistent disability. Pain catastrophising, kinesiophobia (fear of movement), anxiety, depression, perceived stress and low expectations of recovery. Wertli's systematic review (Spine J 2014) confirms that fear-avoidance beliefs are a robust prognostic factor for primary care patients.¹⁰,¹¹
- Lifestyle and work-related factors : low level of physical activity, sleep disorders, heavy physical demands (lifting loads, awkward postures, whole-body vibration).¹
🧠 Hierarchy of prognostic factors for chronicity (2018-2023 synthesis)
Strength of association (relative effect size) between risk factors and progression to chronicity
Qualitative synthesis: the quantitative interpretation of the ORs varies with the definitions used. Sources: Hartvigsen Lancet 2018; Wertli Spine J 2014; Shiri Am J Med 2010; Chiarotto NEJM 2022.1,10,4,9
⚠️ Important nuance : degenerative findings on imaging (disc disease, facet joint osteoarthritis, disc protrusions) are common in asymptomatic individuals and their association with low back pain remains weak or even absent.1,9 This is one of the reasons why imaging is not recommended routinely without a red flag.
What happens in the body, and how does low back pain evolve naturally?
The pathophysiology of non-specific low back pain cannot be reduced to a structural lesion. While acute pain (< 6 weeks) is often initiated by a nociceptive mechanism (activation of pain receptors in the muscles, ligaments, facet joints and annulus fibrosus), progression to chronicity (> 3 months) involves profound neuroplastic changes in the central nervous system.1,9
A key mechanism is central sensitisation, which may be nociplastic according to the 2017 IASP terminology, reconceptualised by Nijs et al. (J Clin Med 2021) under the term “nociplastic pain phenotyping”. It is a hyperexcitability of central nervous system neurons that amplifies pain processing: normally non-painful stimuli can be perceived as painful (allodynia), and painful stimuli are perceived as more intense (hyperalgesia).3 🧠 This phenomenon partly explains why chronic pain persists after tissue healing and why its intensity correlates poorly with imaging findings.1,9
The natural course is generally perceived as favourable in the short term, but this optimistic view needs qualifying.13,14
- Rapid improvement : most patients experience a significant improvement in pain and function within the first 6 weeks. The Itz 2013 review (Eur J Pain) nevertheless reported that ≈ 65 % of patients still report pain at 1 year, calling into question the idea that complete recovery is common.13
- Recurrences : the prospective Stanton 2008 cohort (Spine, n = 973) showed a 12-month recurrence rate of ≈ 33 % using a strict definition, and 73 % using a broad definition: well below historical estimates, but clinically significant.14
- Chronicity : about 20 % of patients with acute low back pain develop chronic low back pain beyond 3 months; the prognosis is less favourable in the presence of catastrophising, leg radiation, low self-efficacy or depression.1,10,11
- The diagnosis of non-specific low back pain is one of exclusion and accounts for 90-95 % of low back pain cases in primary care.1,6
- It is the leading cause of disability worldwide, affecting 619 M people in 2020, and projected to reach 843 M in 2050.2
- Psychosocial factors (catastrophising, kinesiophobia, depression) are the strongest predictors of progression to chronicity.10,11
- Chronicity is sustained by central / nociplastic sensitisation rather than by a persistent structural lesion.3
- The rate of recurrence at 1 year is about 33 % (Stanton 2008): well below historical estimates, but clinically major.14
Bibliography
- Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356-2367. PMID 29573870.
- GBD 2021 Low Back Pain Collaborators. Global, regional, and national burden of low back pain, 1990-2020, its attributable risk factors, and projections to 2050: a systematic analysis of the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(6):e316-e329. PMID 37273833.
- Nijs J, Lahousse A, Kapreli E, et al. Nociplastic Pain Criteria or Recognition of Central Sensitization? Pain Phenotyping in the Past, Present and Future. J Clin Med. 2021;10(15):3203. PMID 34361986.
- Shiri R, Karppinen J, Leino-Arjas P, Solovieva S, Viikari-Juntura E. The association between smoking and low back pain: a meta-analysis. Am J Med. 2010;123(1):87.e7-35. PMID 20102998.
- Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017;389(10070):736-747. PMID 27745712.
- Bardin LD, King P, Maher CG. Diagnostic triage for low back pain: a practical approach for primary care. Med J Aust. 2017;206(6):268-273. PMID 28359011.
- Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. PMID 29573872.
- Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet. 2011;378(9802):1560-1571. PMID 21963002.
- Chiarotto A, Koes BW. Nonspecific Low Back Pain. N Engl J Med. 2022;386(18):1732-1740. PMID 35507483.
- Wertli MM, Rasmussen-Barr E, Weiser S, Bachmann LM, Brunner F. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review. Spine J. 2014;14(5):816-836.e4. PMID 24412032.
- Wertli MM, Rasmussen-Barr E, Held U, Weiser S, Bachmann LM, Brunner F. Fear-avoidance beliefs-a moderator of treatment efficacy in patients with low back pain: a systematic review. Spine J. 2014;14(11):2658-2678. PMID 24614254.
- George SZ, Fritz JM, Silfies SP, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):CPG1-CPG60. PMID 34719942.
- Itz CJ, Geurts JW, van Kleef M, Nelemans P. Clinical course of non-specific low back pain: a systematic review of prospective cohort studies set in primary care. Eur J Pain. 2013;17(1):5-15. PMID 22641374.
- Stanton TR, Henschke N, Maher CG, Refshauge KM, Latimer J, McAuley JH. After an episode of acute low back pain, recurrence is unpredictable and not as common as previously thought. Spine (Phila Pa 1976). 2008;33(26):2923-2928. PMID 19092626.
- Wu A, March L, Zheng X, et al. Global low back pain prevalence and years lived with disability from 1990 to 2017: estimates from the Global Burden of Disease Study 2017. Ann Transl Med. 2020;8(6):299. PMID 32355743.
How can non-specific low back pain be assessed and diagnosed with certainty?

X-rayAP lumbar spine radiograph interpreted as normal, illustrating the frequent absence of visible structural abnormality in non-specific low back pain.
Source : Pringle et al., Chiropractic & osteopathy, 2006, figure 1 · CC BY
The assessment of non-specific low back pain (NSLBP) aims less at making a pathognomonic diagnosis than at ruling out serious conditions and identifying the patient's profile to guide treatment.¹,² The modern approach, supported by clinical practice guidelines (APTA George 2021, NICE NG59, Stochkendahl 2018 Eur Spine J), is patient-centred and rests on a biopsychosocial model.³,⁴,⁵ 🧠
Which questions should you ask to understand the patient and their history?
History-taking is the cornerstone of diagnosis. It should identify the relevant factors while building a solid therapeutic alliance. The initial objective is rigorous triage to screen for “red flags” : signs or symptoms that may indicate a serious underlying condition (fracture, infection, tumour, cauda equina syndrome).¹,⁶ Although the prevalence of these conditions is low (< 1 to 5 % of cases in primary care depending on the setting), identifying them is crucial.²
Red flags to screen for systematically
- Vertebral fracture : recent significant trauma (fall, road traffic accident); prolonged corticosteroid therapy; age > 70 years; known osteoporosis.6,7
- Malignancy / metastases : personal history of cancer (the highest sensitivity, Henschke Cochrane 2013); unexplained weight loss; non-mechanical night pain; age > 50 years; no improvement after 4-6 weeks.6,7,8
- Infection (spondylodiscitis, epidural abscess) : fever, chills; immunosuppression; IV drug use; recent spinal procedure; constant non-mechanical pain.1,6
- Cauda equina syndrome 🚨 (surgical emergency): urinary retention with overflow incontinence, sphincter incontinence, saddle anaesthesia, progressive bilateral motor deficit.1,3
- Abdominal aortic aneurysm : deep, pulsatile low back pain, abdominal mass; older patient who smokes and has hypertension.10
- Inflammatory spondyloarthritis : age < 40 years, morning stiffness > 30 min, improvement with exercise, night waking in the second half of the night, family history of HLA-B27.9
⚠️ Fundamental nuance : the diagnostic validity of isolated red flags is low. Verhagen's review (Pain 2017) showed that most of the red flags in guidelines lack solid empirical validation, and Premkumar (JBJS 2018) observed that 64 % of patients with spinal malignancy had no associated red flag. Their strength lies in their combination and longitudinal analysis (reassess if there is no improvement after 4-6 weeks).7,8
Beyond red flags, the assessment should identify “yellow flags” : psychosocial factors predictive of chronicity.¹²,¹³ Asking about them actively is essential:
- Beliefs and cognitions : catastrophising, kinesiophobia, negative expectations of recovery.11
- Emotional responses : symptoms of depression or anxiety.12
- Pain-related behaviours : avoidance strategies, overuse of care, low self-efficacy.12
Which clinical tests should be performed, and which other conditions must be ruled out?

MRISagittal lumbar MRI showing severe disc degeneration at L5-S1 with a disc protrusion, without associated nerve compression.
Source : Külling et al., Orthopaedic journal of sports medicine, 2014, figure 1 · CC BY-NC-ND
Bardin's diagnostic triage (Med J Aust 2017), adopted by most international guidelines, structures the reasoning into 3 mutually exclusive categories:
🧭 Diagnostic triage of low back pain into 3 categories (Bardin 2017)
From initial presentation to categorisation: the recommended clinical pathway
Source: Bardin LD, King P, Maher CG. Med J Aust. 2017;206(6):268-273. PMID 28359011.
The physical examination should systematically include:
- Inspection of posture and spinal curves.
- Assessment of active range of motion of the lumbar spine (flexion, extension, side bending, rotation): movement quality, symptom response.
- Targeted neurological examination if radiculopathy is suspected: motor strength (myotomes L2 to S1), sensation (dermatomes), reflexes (patellar L4, Achilles S1).⁵
- Neural tension tests : the passive leg-raise test (Straight Leg Raise, Lasègue): generally high sensitivity but low specificity for low lumbar disc-related nerve root compression. The crossed SLR (pain in the symptomatic leg when the contralateral leg is raised) is more specific.5,9
🚫 Imaging is NOT recommended routinely for NSLBP without a red flag. APTA George 2021, NICE NG59, Stochkendahl 2018 and the Choosing Wisely campaign agree: early imaging does not change management, may reveal “incidental” abnormalities (disc disease, osteoarthritis) unrelated to the pain, and is associated with a nocebo effect (anxiety, over-medicalisation).3,4,15
Should patients with low back pain be classified, and for what benefits?
Patient stratification moves beyond the “one size fits all” model and points towards targeted management.¹⁴ ✅ A widely studied tool is the STarT Back Screening Tool (9-item self-report questionnaire), which classifies patients into 3 groups by their risk (low / medium / high) of developing chronic disability.¹⁴
📊 STarT Back stratification: 3 risk groups + matched care
Hill JC et al. Lancet 2011, RCT n = 851: slightly lower disability at 12 months (1.06 points on the RMDQ) and lower costs; divergent results in subsequent trials
Source: Hill JC et al. Lancet. 2011;378(9802):1560-1571. PMID 21963002. Distribution of the trial's 851 patients; at 12 months, the advantage of the stratified pathway is significant only for medium risk, not for high risk.
Other systems exist: mechanism-based classifications (nociceptive, neuropathic, nociplastic pain according to Nijs 2021), McKenzie / Mechanical Diagnosis and Therapy, biopsychosocial classifications. None has shown definitive superiority. STarT Back has been evaluated in at least seven randomised trials : in Hill 2011 (851 patients), the stratified pathway reduced disability slightly more at 12 months (1.06 points on the RMDQ), at lower cost;¹⁴ the subsequent trials are discussed below.
Critique and controversy
First, the validity of isolated red flags is low. The Henschke review (Cochrane 2013) already concluded that “for most red flags, there is insufficient evidence to provide recommendations on their diagnostic accuracy”.⁹ The Verhagen 2017 review (Pain) reinforces this point for malignancy flags. Their strength comes from their combination and from clinical follow-up.7,8
Second, the results of STarT Back stratification diverge from one trial to another. The tool's authors list at least seven trials in four countries, some favourable, others showing no benefit, and attribute the gap mainly to implementation difficulties.¹⁷ A meta-analysis of five trials in acute low back pain finds only a very small reduction in pain, with no difference in disability, on very low certainty evidence.¹⁸ In the United States, the TARGET trial (2,300 high-risk patients) does not reduce progression to chronicity,¹⁹ and the Rhon 2023 trial (270 patients) does no better than usual care at 1 year;²⁰ its economic analysis does not find stratified care cost-effective for low and medium risk, and high risk remains to be evaluated,²¹ since the trial included only 21 high-risk patients.²⁰ NICE still recommends considering stratification.⁴
Finally, the very concept of “non-specific low back pain” is debated. Some experts argue that the term masks real heterogeneity and hinders the search for relevant subgroups. Research is moving towards more precise phenotypes that integrate clinical, psychosocial and biological data.1,3
- The assessment must systematically look for and rule out red flags before concluding that the low back pain is non-specific.6,7
- The Bardin diagnostic triad structures the reasoning: non-specific 90-95 % / radicular 5-10 % / specific pathology < 1 %.6
- Assessment of yellow flags (catastrophising, kinesiophobia) is as important as the physical examination for predicting chronicity.10,11
- Imaging is not indicated routinely without a red flag: APTA 2021, NICE NG59 and Stochkendahl 2018 agree on this point.3,4,15
- The STarT Back Tool (3 risk groups) classifies patients according to their risk of chronicity; the stratified pathway slightly reduced disability and costs in the Hill 2011 trial, but subsequent trials diverge.¹⁴,¹⁷
Bibliography
- Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356-2367. PMID 29573870.
- Oliveira CB, Maher CG, Pinto RZ, et al. Clinical practice guidelines for the management of non-specific low back pain in primary care: an updated overview. Eur Spine J. 2018;27(11):2791-2803. PMID 29971708.
- George SZ, Fritz JM, Silfies SP, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):CPG1-CPG60. PMID 34719942.
- National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE Guideline NG59. London: NICE; 2016, last updated 29 July 2026. www.nice.org.uk/guidance/ng59.
- Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Eur Spine J. 2018;27(1):60-75. PMID 28429142.
- Bardin LD, King P, Maher CG. Diagnostic triage for low back pain: a practical approach for primary care. Med J Aust. 2017;206(6):268-273. PMID 28359011.
- Downie A, Williams CM, Henschke N, et al. Red flags to screen for malignancy and fracture in patients with low back pain: systematic review. BMJ. 2013;347:f7095. PMID 24335669.
- Premkumar A, Godfrey W, Gottschalk MB, Boden SD. Red Flags for Low Back Pain Are Not Always Really Red: A Prospective Evaluation of the Clinical Utility of Commonly Used Screening Questions for Low Back Pain. J Bone Joint Surg Am. 2018;100(5):368-374. PMID 29509613.
- Henschke N, Maher CG, Ostelo RW, de Vet HC, Macaskill P, Irwig L. Red flags to screen for malignancy in patients with low-back pain. Cochrane Database Syst Rev. 2013;(2):CD008686. PMID 23450586.
- Verhagen AP, Downie A, Popal N, Maher C, Koes BW. Red flags presented in current low back pain guidelines: a review. Eur Spine J. 2016;25(9):2788-2802. PMID 27376890.
- Verhagen AP, Downie A, Maher CG, Koes BW. Most red flags for malignancy in low back pain guidelines lack empirical support: a systematic review. Pain. 2017;158(10):1860-1868. PMID 28708761.
- Maher C, Underwood M, Buchbinder R. Non-specific low back pain. Lancet. 2017;389(10070):736-747. PMID 27745712.
- Wertli MM, Rasmussen-Barr E, Weiser S, Bachmann LM, Brunner F. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review. Spine J. 2014;14(5):816-836.e4. PMID 24412032.
- Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet. 2011;378(9802):1560-1571. PMID 21963002.
- Chiarotto A, Koes BW. Nonspecific Low Back Pain. N Engl J Med. 2022;386(18):1732-1740. PMID 35507483.
- Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. PMID 29573872.
- Croft P, Hill JC, Foster NE, Dunn KM, van der Windt DA. Stratified health care for low back pain using the STarT Back approach: holy grail or doomed to fail? Pain. 2024;165(12):2679-2692. PMID 39037849.
- Chiodo AF, Haley M. Does risk stratification with a matched treatment pathway improve clinical outcomes for adults with acute back pain? A systematic review and meta-analysis. Braz J Phys Ther. 2024;28(5):101116. PMID 39270550.
- Delitto A, Patterson CG, Stevans JM, et al. Stratified care to prevent chronic low back pain in high-risk patients: The TARGET trial. A multi-site pragmatic cluster randomized trial. EClinicalMedicine. 2021;34:100795. PMID 33870150.
- Rhon DI, Greenlee TA, Poehlein E, et al. Effect of Risk-Stratified Care on Disability Among Adults With Low Back Pain Treated in the Military Health System: A Randomized Clinical Trial. JAMA Netw Open. 2023;6(7):e2321929. PMID 37410465.
- Rhon DI, Kim M, Asche C, George SZ. Cost-effectiveness of Risk Stratified Care Versus Usual Care for Low Back Pain in the Military Health System. Spine (Phila Pa 1976). 2025;50(14):E270-E277. PMID 39239790.
Which treatment strategies are most effective for non-specific low back pain?
Where do you start? What is the recommended hierarchy of interventions?
The initial approach to non-specific low back pain (NSLBP), whether acute or chronic, is the subject of a strong international consensus. 🔍 The first line is non-pharmacological and combines patient education, advice to stay active and self-management (APTA George 2021, NICE NG59, Stochkendahl 2018 Eur Spine J, Foster Lancet 2018).¹,²,³,⁴ Imaging should be avoided without a red flag, and opioids are strongly discouraged in chronic pain.¹,²
The British model of risk stratification (STarT Back) adapts treatment intensity to the patient's profile; the session volumes below are a practical guide, not a validated dose:⁵
- Low risk : advice, education, encouragement of self-management; 1-2 sessions are often enough.
- Medium risk : standard physiotherapy (graded exercise + education), 4 to 6 sessions.
- High risk : psychologically informed physiotherapy (graded exercise, education, management of psychosocial factors, for example CFT), 8 to 12 sessions.
📋 Comparison table of modalities x GRADE level of evidence: chronic low back pain
Synthesis of the APTA 2021, NICE NG59 and Stochkendahl 2018 guidelines and of meta-analyses
| Modality | GRADE level | Expected effect | Main source |
|---|---|---|---|
| Education + advice to stay active | High | Reduces disability and healthcare use | APTA 2021; Lancet 2018 |
| Therapeutic exercise (any type) | Moderate | Reduces pain; small effect on disability, possibly below the clinical threshold | Hayden Cochrane 2021 |
| Cognitive Functional Therapy (CFT) | Moderate (one unblinded trial) | Clinically signif. reduction in RMDQ at 13 wks; effect maintained at 3 years (312 of 492 participants followed up) | Kent Lancet 2023; Hancock 2025 |
| STarT Back stratification | Low (editorial judgement) | Modest gain in Hill 2011, not found in several subsequent trials; NICE still recommends it | Hill Lancet 2011; Croft 2024; Rhon 2023 |
| Manual therapy (spinal manipulation) | Low to very low | Versus other conservative interventions: little or no difference in pain, small gain in function at one month | Cochrane de Zoete 2026 |
| Oral NSAIDs (acute LBP) | Low to very low | Comparative effectiveness uncertain; NICE: consider, at the lowest dose for the shortest time | Wewege BMJ 2023 (NMA); NICE NG59 |
| Paracetamol (acute LBP) | Low | No more effective than placebo in several trials | NICE NG59; APTA 2021 |
| Pain neuroscience education alone (intensive PNE) | Moderate | Not superior to placebo education in acute pain | Traeger JAMA Neurol 2019 |
| Opioids (acute) | One placebo-controlled trial | No significant difference in pain at 6 weeks, more opioid-related adverse effects; NICE: not routinely | OPAL Lancet 2023; NICE NG59 |
| Opioids (chronic) | Low | Marginal benefit vs risk; NICE: do not offer | APTA 2021; NICE NG59 |
| Routine imaging (no red flag) | Not recommended | No improvement in outcomes; nocebo effect | APTA 2021; NICE NG59 |
| Traction, ultrasound, laser, TENS | Low | Insufficient evidence to recommend them routinely | NICE NG59; Stochkendahl 2018 |
What is the place of exercise, and is there a superior approach?
Therapeutic exercise is the intervention most robustly supported, particularly for chronic low back pain. 💪 The Cochrane review by Hayden 2021 (249 trials, > 24,000 participants) concludes, with MODERATE certainty, that exercise probably reduces pain; the effect on functional disability is described there as small and possibly of no clinical relevance.⁶
The question of the superiority of one type remains widely debated. The network meta-analysis by Owen 2020 (BJSM), which compared 13 exercise modes across 89 trials, concludes that approaches such as Pilates, stabilisation exercises, McKenzie, yoga produce broadly similar benefits; aerobic + strengthening exercise and Pilates come out slightly ahead for pain, with no clinically decisive difference in function.⁷ Motor control exercise (Cochrane Saragiotto 2016) is not significantly superior to other forms of active exercise or to manual therapy.⁸
The most decisive factor in the success of an exercise programme is not its nature but the patient's adherence.⁶ The choice should therefore be guided by preferences, abilities, goals and context (athletic, sedentary, lifestyle) to maximise long-term engagement.
Manual therapies, technologies: how effective are they really?
The use of manual therapy (mobilisation, spinal manipulation) may bring a short-term benefit. The Cochrane review by de Zoete 2026 on chronic low back pain (76 RCTs, 11,866 participants, search closed in October 2024), which updates the 2011 Cochrane review, rates the evidence as low to very low certainty: against placebo, manipulation might slightly reduce pain at one month, but this is very uncertain; against other conservative interventions, it makes little or no difference to pain and slightly improves function.¹⁷ The Rubinstein 2019 meta-analysis (BMJ, 47 RCTs), by the same team, concluded that its effects were similar to those of recommended therapies for chronic low back pain in the short term; the 2026 Cochrane review lowers the certainty of this finding.⁹
Manual therapy fits in as a complement to an active approach: NICE only considers it within a programme that includes exercise.⁴ In the UK BEAM trial (BMJ 2004, 1,334 patients), manipulation followed by exercise provided, compared with best care from the general practitioner, a moderate benefit at 3 months and a small one at 12 months.¹⁹ In PACBACK (JAMA 2026, 1,000 patients with acute or subacute low back pain at risk of chronicity), supported self-management, with or without manipulation, slightly reduced disability over one year compared with medical care, whereas manipulation alone did not.¹⁸
🔌 As for passive technologies (ultrasound, laser, traction, TENS, shockwave), the international guidelines agree: insufficient evidence to recommend them routinely.2,3,4 Acupuncture holds an ambiguous position depending on the guideline.
🩺 As regards pharmacology, the network meta-analysis by Wewege 2023 (BMJ, 98 RCTs, > 15,000 participants) on analgesics in acute low back pain concludes that their comparative effectiveness and safety remain uncertain, with confidence in most estimates being low to very low, and urges caution;¹⁰ NICE suggests considering an oral NSAID, at the lowest effective dose for the shortest possible time, and not offering paracetamol alone.⁴ For opioids, the OPAL trial (Lancet 2023, 347 adults with acute low back pain or neck pain, oxycodone-naloxone for up to 6 weeks) finds no significant difference in pain at 6 weeks versus placebo, with more opioid-related adverse effects;²⁰ NICE recommends not offering them routinely in acute low back pain, and not offering them in chronic low back pain.⁴
Beyond the physical: how do you educate the patient and address psychological factors?
🧠 Patient education aims to reconceptualise pain : not as a signal of proportional tissue damage, but as a protective measure of the nervous system, modulated by multiple factors (cognitive, emotional, contextual).¹¹ Pain Neuroscience Education (PNE), as synthesised by Louw 2016, has shown broadly favourable effects on pain knowledge, but modest clinical effects in isolation.¹¹
⚠️ Important nuance: the randomised trial by Traeger 2019 (JAMA Neurol, n = 202) in acute low back pain showed that 2 h of intensive PNE was NOT superior to reassuring placebo education on outcomes at 3 months.¹² Pragmatic conclusion: the key message is to reassure and encourage movement ; the scientific exhaustiveness of what is said is not an end in itself.
For patients with marked psychosocial factors, psychologically informed approaches (PIPT) integrate cognitive and behavioural techniques into physiotherapy. The most promising approach is Cognitive Functional Therapy (CFT). In July 2026, NICE withdrew from NG59 its recommendations on psychological therapy and on combined physical and psychological programmes: they relied partly on evidence that has since been retracted, and updating them was not prioritised, as its committee judged that this would have little effect on clinical practice.⁴
🌟 The pivotal RESTORE trial (Kent et al., Lancet 2023, n = 492 adults with disabling chronic low back pain ≥ 3 months, 3-arm parallel design) compared CFT vs CFT + sensor biofeedback vs usual care:¹³
- Primary outcome at 13 weeks : reduction in the Roland-Morris Disability Questionnaire (RMDQ), with highly significant superiority of both CFT arms vs control (mean difference ≈ 4-5 points out of 24, clinically and statistically significant).
- Effects maintained at 1 year (initial publication) and persistence at 3 years in the 312 of 492 participants followed up, according to Hancock et al. (Lancet Rheumatol 2025).¹⁴
- Mechanism : graded exposure to feared activities, cognitive reconceptualisation of pain, restoration of the patient's self-confidence.
CFT illustrates the rigorous implementation of the biopsychosocial model. It does, however, require specific training and advanced communication skills, which are not universally widespread.¹³,¹⁵
Critique and controversy
Despite convergent, evidence-based guidelines, a large gap persists between recommendations and practice.² Over-prescription of imaging, opioids and rest remains common, including in high-income countries. First-line interventions (education, advice on activity) are underused.
The search for the “best” exercise or the “best” manual technique is often a false problem. Network meta-analyses show differences that are statistically significant but clinically slim. The future lies in individualisation, in shared decision-making and in strengthening the therapeutic alliance.
The efficacy of CFT, although demonstrated by RESTORE, raises implementation questions: how many clinicians are trained? Which providers (physiotherapist alone, multidisciplinary team)? What cost-effectiveness at the scale of a health system?¹³,¹⁴
- First line: education + advice to stay active + self-management. Imaging should be avoided without a red flag.1,2,3
- Exercise: a pivotal intervention in chronic low back pain (moderate certainty, Hayden 2021). No type is universally superior : choose according to preferences to maximise adherence.6,7
- Passive therapies: manual therapy = possible short-term benefit in chronic low back pain, on low to very low certainty evidence (Cochrane 2026), as a complement to an active approach. The other passive technologies have weak evidence.9,17
- CFT (RESTORE Lancet 2023): a highly significant reduction in disability in disabled chronic patients, with effects maintained at 3 years in the 312 of 492 participants followed up (Hancock 2025).13,14
- Pharmacology: comparative effectiveness of analgesics uncertain (Wewege 2023); NICE: consider an oral NSAID, no paracetamol alone; opioids not routinely in acute pain (OPAL, NICE), not to be offered in chronic pain (NICE).10,20,4
Bibliography
- George SZ, Fritz JM, Silfies SP, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):CPG1-CPG60. PMID 34719942.
- Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. PMID 29573872.
- Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Eur Spine J. 2018;27(1):60-75. PMID 28429142.
- National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE Guideline NG59. London: NICE; 2016, last updated 29 July 2026. www.nice.org.uk/guidance/ng59.
- Hill JC, Whitehurst DG, Lewis M, et al. Comparison of stratified primary care management for low back pain with current best practice (STarT Back): a randomised controlled trial. Lancet. 2011;378(9802):1560-1571. PMID 21963002.
- Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MW. Exercise therapy for chronic low back pain. Cochrane Database Syst Rev. 2021;9(9):CD009790. PMID 34580864.
- Owen PJ, Miller CT, Mundell NL, et al. Which specific modes of exercise training are most effective for treating low back pain? Network meta-analysis. Br J Sports Med. 2020;54(21):1279-1287. PMID 31666220.
- Saragiotto BT, Maher CG, Yamato TP, et al. Motor control exercise for chronic non-specific low-back pain. Cochrane Database Syst Rev. 2016;1(1):CD012004. PMID 26742533.
- Rubinstein SM, de Zoete A, van Middelkoop M, et al. Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;364:l689. PMID 30867144.
- Wewege MA, Bagg MK, Jones MD, Ferraro MC, Cashin AG, et al. Comparative effectiveness and safety of analgesic medicines for adults with acute non-specific low back pain: systematic review and network meta-analysis. BMJ. 2023;380:e072962. PMID 36948512.
- Louw A, Zimney K, Puentedura EJ, Diener I. The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature. Physiother Theory Pract. 2016;32(5):332-355. PMID 27351541.
- Traeger AC, Lee H, Hubscher M, et al. Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain: A Randomized Clinical Trial. JAMA Neurol. 2019;76(2):161-169. PMID 30398542.
- Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial. Lancet. 2023;401(10391):1866-1877. PMID 37146623.
- Hancock M, Smith A, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial. Lancet Rheumatol. 2025;7(11):e789-e798. PMID 40780241.
- O'Sullivan PB, Caneiro JP, O'Keeffe M, et al. Cognitive Functional Therapy: An Integrated Behavioral Approach for the Targeted Management of Disabling Low Back Pain. Phys Ther. 2018;98(5):408-423. PMID 29669082.
- Saragiotto BT, Abdel Shaheed C, Overton M, Hayden JA, Hartvigsen J, Pinto RZ. Recent highlights in low back pain research, Part II: Prevention and management. J Physiother. 2026;72(2):106-115. PMID 41933950.
- de Zoete A, Innocenti T, Petrozzi MJ, et al. Spinal manipulative therapy for adults with chronic low back pain. Cochrane Database Syst Rev. 2026;1(1):CD008112. PMID 41494147.
- Bronfort G, Meier EN, Leininger B, et al. Spinal Manipulation and Clinician-Supported Biopsychosocial Self-Management for Acute Back Pain: The PACBACK Randomized Clinical Trial. JAMA. 2026;335(6):497-510. PMID 41460638.
- UK BEAM Trial Team. United Kingdom back pain exercise and manipulation (UK BEAM) randomised trial: effectiveness of physical treatments for back pain in primary care. BMJ. 2004;329(7479):1377. PMID 15556955.
- Jones CMP, Day RO, Koes BW, et al. Opioid analgesia for acute low back pain and neck pain (the OPAL trial): a randomised placebo-controlled trial. Lancet. 2023;402(10398):304-312. PMID 37392748.
How do you secure lasting recovery and prevent recurrence of non-specific low back pain?
Non-specific low back pain has a high recurrence rate : the Stanton 2008 cohort (Spine, n = 973) documented ≈ 33 % recurrence at 1 year using a strict definition, and up to 73 % using a broad definition.¹ These figures are markedly lower than historical estimates (often > 60 %) but remain clinically major. The shift from a purely biomedical approach to a biopsychosocial model is now recognised as fundamental to breaking this cycle.²,³
How can the patient become an active agent in their own recovery through self-management?
The patient's own management of the condition (self-management) is the cornerstone of recurrence prevention.²,³ It aims to give the patient the autonomy, confidence and skills needed to manage their symptoms, reduce their limitations and minimise the impact of pain. 🧘♀️
The two pillars of effective self-management are education and exercise :
- Therapeutic education : the modern approach (Pain Neuroscience Education, PNE) aims to reconceptualise pain. The systematic review by Louw 2016 confirms a favourable effect on knowledge and disability, particularly when it is integrated into an active intervention.⁴ The intermediate review by Traeger 2019 adds nuance: 2 h of intensive PNE is no better than reassuring placebo education in acute pain, evidence that the reassuring message + movement are what matters most.⁵
- Therapeutic exercise : the Cochrane review by Hayden 2021 confirms the efficacy of exercise for chronic low back pain. The de Campos 2021 review (BJSM, formerly Steffens 2016; meta-analysis of 25 RCTs, > 9,000 participants) confirms that exercise combined with education reduces the risk of recurrence by about 45 % at 1 year.⁶,⁷ The type of exercise matters less than adherence and regularity.⁸
📉 Reduction in recurrence risk: exercise + education
de Campos et al., BJSM 2021: meta-analysis of prevention strategies
Sources: de Campos TF et al. Br J Sports Med. 2021 (PMID 32646887); Steffens D et al. JAMA Intern Med. 2016;176(2):199-208 (PMID 26752509).
The emphasis should be on finding an activity the patient enjoys and will keep up in the long term, fostering self-efficacy and an active lifestyle that is protective overall.⁶,⁷
When and how should a safe return to sport and activities be planned?
Return to sport (RTS) after low back pain must be structured and criteria-based, not based on an arbitrary timetable. 🏆 The aim is to ensure that the patient's musculoskeletal system tolerates the specific demands of the target activity without triggering a new episode.
A progressive consensus has formed around a staged approach:
- Phase 1: Pain control and basic functional recovery. Activities of daily living without significant pain. Lumbar and hip range of motion restored.
- Phase 2: Strengthening and neuromuscular control. Strength and endurance of the trunk muscles (core stability), gluteals, lower limbs. Movement quality during functional exercises.
- Phase 3: Sport-specific functional tests. Jumps, changes of direction, sprints, lifting loads: pain-free and with good kinematics.
- Phase 4: Progressive, graded return. Volume and intensity reduced initially. Monitoring of training load is crucial: sudden increases are a major risk factor (Gabbett BJSM 2016, training-injury prevention paradox).⁹
- Phase 5: Psychological assessment. The patient's confidence to move and perform without fear is an essential criterion. Residual kinesiophobia can alter motor patterns and promote recurrence.10,11
Critique and controversy
🧐 The “non-specific” paradox : the label that groups nearly 90 % of cases is increasingly criticised. It masks a real heterogeneity. Efforts are under way to develop subgroups (nociceptive / nociplastic mechanisms according to Nijs 2021, movement profiles), but no method commands unanimous agreement.10
🥋 The war of exercise brands (Pilates vs McKenzie vs core stability) continues to influence clinicians and the public, whereas meta-analyses conclude that there is pragmatic equivalence. Long-term adherence is the decisive element.7,8
📚 Implementing PNE remains a challenge: it cannot be reduced to a leaflet or a 5-minute explanation. It requires time, communication skills and a genuine therapeutic alliance. Its effect, although real, remains modest, and it absolutely must be combined with an active approach.4,5
- ✅ Empower the patient through self-management (education + exercise).2,3
- 🧠 Change beliefs with PNE, combined with an active approach.4
- 💪 Move more, move better : promote regular, enjoyable physical activity; adherence matters more than specificity.6,7,8
- 📉 Combining exercise + education reduces the risk of recurrence by about 45 % at 1 year.6
- 🏆 Smart return to sport : functional and psychological criteria, not the calendar; load monitoring.9
Bibliography
- Stanton TR, Henschke N, Maher CG, Refshauge KM, Latimer J, McAuley JH. After an episode of acute low back pain, recurrence is unpredictable and not as common as previously thought. Spine (Phila Pa 1976). 2008;33(26):2923-2928. PMID 19092626.
- Hartvigsen J, Hancock MJ, Kongsted A, et al. What low back pain is and why we need to pay attention. Lancet. 2018;391(10137):2356-2367. PMID 29573870.
- Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. PMID 29573872.
- Louw A, Zimney K, Puentedura EJ, Diener I. The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature. Physiother Theory Pract. 2016;32(5):332-355. PMID 27351541.
- Traeger AC, Lee H, Hubscher M, et al. Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain: A Randomized Clinical Trial. JAMA Neurol. 2019;76(2):161-169. PMID 30398542.
- de Campos TF, Maher CG, Fuller JT, Steffens D, Attwell S, Hancock MJ. Prevention strategies to reduce future impact of low back pain: a systematic review and meta-analysis. Br J Sports Med. 2021;55(9):468-476. PMID 32646887.
- Steffens D, Maher CG, Pereira LS, et al. Prevention of Low Back Pain: A Systematic Review and Meta-analysis. JAMA Intern Med. 2016;176(2):199-208. PMID 26752509.
- Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MW. Exercise therapy for chronic low back pain. Cochrane Database Syst Rev. 2021;9(9):CD009790. PMID 34580864.
- Gabbett TJ. The training-injury prevention paradox: should athletes be training smarter and harder? Br J Sports Med. 2016;50(5):273-280. PMID 26758673.
- Nijs J, Lahousse A, Kapreli E, et al. Nociplastic Pain Criteria or Recognition of Central Sensitization? Pain Phenotyping in the Past, Present and Future. J Clin Med. 2021;10(15):3203. PMID 34361986.
- Wertli MM, Rasmussen-Barr E, Held U, Weiser S, Bachmann LM, Brunner F. Fear-avoidance beliefs-a moderator of treatment efficacy in patients with low back pain: a systematic review. Spine J. 2014;14(11):2658-2678. PMID 24614254.
What do real clinical cases teach us about non-specific low back pain?
Beyond systematic reviews and randomised controlled trials, clinical cases and case series offer a valuable window onto the practical application of therapeutic strategies. They illustrate the complexity, individuality and pitfalls of clinical reasoning in non-specific low back pain. 🧐 ⚠️ Level of evidence: low (Oxford CEBM 4-5). Clinical cases are not evidence of efficacy, but they are powerful teaching tools when they come from the published literature.
Analysis of a classic case: from assessment to resolution
The most common profile in practice is a patient of working age (30-55 years), with persistent common low back pain of 2 to 6 months' duration, no red flag, moderate functional disability (RMDQ 8-12 / 24, Oswestry 20-40 %) and moderate psychosocial factors (FABQ-W > 15, PCS > 20).
The evidence-based approach for this profile, supported by George 2021 (APTA CPG), Foster Lancet 2018 and Hayden Cochrane 2021, combines 3 pillars:¹,²,³
- Education and reassurance : explaining the multifactorial nature of pain, decoupling the sensation from tissue damage, encouraging movement. PNE is integrated pragmatically without overloading the patient with information.4,5
- Manual therapy (short term) : used to modulate pain, improve joint mobility and create a window of opportunity for movement. Expected effects are small, on low to very low certainty evidence (Cochrane 2026),¹⁶ to be combined with an active approach (Rubinstein BMJ 2019).⁶
- Progressive exercise : an individualised programme (preferences, capacity, lifestyle), with graded exposure to feared movements or activities. Aerobic + strengthening + mobility. No type is universally superior.7,8
Over 8 to 12 weeks, the typical expectations are:
- Reduction in pain (NPRS) of 2 to 4 points (MCID ≈ 2 points out of 11).
- Improvement in disability (RMDQ or Oswestry) beyond the MCID (≈ 5 points out of 24 or ≈ 10 points out of 100, respectively).
- Reduction in kinesiophobia (TSK) and in catastrophising (PCS).
- Progressive return to work and sporting activities.
✅ This multimodal approach is consistent with the literature and with the most recent international guidelines (APTA 2021, NICE NG59, Stochkendahl 2018, Saragiotto 2026 Part II).1,9,10,11
The diagnostic challenge: when low back pain mimics another condition
The “non-specific” label NEVER removes the need for constant vigilance. The Downie 2013 review (BMJ) and Premkumar 2018 (JBJS) recall the importance, and the limits, of red flag screening. 🩺
3 major families of serious conditions never to miss
- Vascular conditions : an abdominal aortic aneurysm that is leaking may present as sudden, deep, pulsatile low back pain in an older patient who smokes and has hypertension. Palpation of a pulsatile abdominal mass, sudden hypotension and pain with atypical radiation are warning signs. Absolute vascular emergency.
- Infectious conditions : the pyogenic form of spondylodiscitis (most often Staphylococcus aureus) preferentially affects diabetic, immunocompromised and post-surgical patients and IV drug users. Presentation: severe non-mechanical low back pain, intermittent fever, raised inflammatory markers, characteristic MRI. Requires prolonged antibiotic therapy.
- Tumoural conditions : vertebral metastases (breast, lung, prostate, kidney, thyroid) are the most common cause of spinal tumour. Highest sensitivity: history of cancer (Henschke Cochrane 2013).13 Presentation: progressive, nocturnal, non-mechanical pain; neurological signs in the event of spinal cord compression.
⚠️ Combined warning pattern : combining several flags with a longitudinal analysis is crucial. Low back pain that does not improve after 4-6 weeks of appropriate management, or that worsens, warrants a systematic reassessment of red flags and medical referral.
Study of a complex case: the RESTORE trial
Rather than a fictitious clinical case, let us illustrate with the pivotal RESTORE trial (Kent et al., Lancet 2023): n = 492 Australian adults with disabling chronic low back pain for ≥ 3 months (median 4 years), with mean scores of RMDQ ≈ 12 / 24 and NPRS ≈ 6 / 10 at baseline.¹²
Typical participant profile : chronic patients already seen in primary care, having tried several interventions (conventional physiotherapy, NSAIDs, lumbar braces, sometimes injections), with high kinesiophobia (high TSK), low self-efficacy and pessimistic beliefs about the possibility of recovery.
CFT intervention (up to 7 sessions, 11 weeks + 2 boosters): ¹²,¹⁴
- Making sense : exploring the patient's history and beliefs, identifying protective behaviours (avoidance, muscle guarding) that maintain the pain-disability cycle.
- Graded exposure to movement and feared activities, with regulation strategies (breathing, relaxation, free trunk movement).
- Restoring a healthy lifestyle : sleep, physical activity, stress management, gradual return to work.
Main results :
- At 13 weeks : mean difference of −4.6 points on the RMDQ (95 % CI −5.9 to −3.4) between CFT and usual care: clinically and statistically significant superiority.
- At 1 year : effect maintained on disability and quality of life (initial publication).
- At 3 years (Hancock 2025, Lancet Rheumatol) : persistence of effects on disability in the 312 of 492 participants followed up, a result presented by its authors as new for a non-pharmacological conservative intervention in disabling chronic low back pain.14
- Sensor biofeedback brought no additional benefit over CFT alone, suggesting that the active ingredient is the targeted cognitive behavioural therapy, not the technological gadget.
Critique and controversy
🤔 Individual clinical cases have a very low level of evidence (Oxford CEBM 4-5). A spectacular success in an isolated case does not guarantee efficacy on a larger scale and may result from multiple confounding factors (placebo effect, natural history, therapist charisma). They should be read as illustrations of principles, never as evidence in themselves.
Evidence pyramid: quick read (presented as horizontal cards for easy reading):
📐 GRADE / Oxford CEBM hierarchy for non-specific low back pain
Levels of evidence presented as horizontal cards (never as an unreadable text pyramid)
How to read it: the higher you go (green), the stronger the level of evidence. Clinical cases (level 4) are educational but not sufficient to formulate recommendations.
🗂️ The very concept of “non-specific low back pain” : the label that covers ≈ 90 % of cases is increasingly debated. Mechanism-based classification models (nociceptive / neuropathic / nociplastic) or movement-profile models could allow more targeted therapies.15,1
- Classic clinical cases illustrate a multimodal approach (education + short-term manual therapy + progressive exercise), in line with the guidelines; they do not demonstrate its superiority.1,2,3
- The need for vigilance remains paramount : vascular (aortic aneurysm), infectious (spondylodiscitis) and tumoural (metastases) conditions can mimic common low back pain.13
- The RESTORE (Lancet 2023) trial showed clinically significant superiority of CFT in disabled chronic patients, maintained at 3 years in the 312 of 492 participants followed up.12,14
- Clinical cases are powerful teaching tools but have a low level of evidence : use them as illustrations, not as rules.
Bibliography
- George SZ, Fritz JM, Silfies SP, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):CPG1-CPG60. PMID 34719942.
- Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. PMID 29573872.
- Hayden JA, Ellis J, Ogilvie R, Malmivaara A, van Tulder MW. Exercise therapy for chronic low back pain. Cochrane Database Syst Rev. 2021;9(9):CD009790. PMID 34580864.
- Louw A, Zimney K, Puentedura EJ, Diener I. The efficacy of pain neuroscience education on musculoskeletal pain: A systematic review of the literature. Physiother Theory Pract. 2016;32(5):332-355. PMID 27351541.
- Traeger AC, Lee H, Hubscher M, et al. Effect of Intensive Patient Education vs Placebo Patient Education on Outcomes in Patients With Acute Low Back Pain: A Randomized Clinical Trial. JAMA Neurol. 2019;76(2):161-169. PMID 30398542.
- Rubinstein SM, de Zoete A, van Middelkoop M, et al. Benefits and harms of spinal manipulative therapy for the treatment of chronic low back pain: systematic review and meta-analysis of randomised controlled trials. BMJ. 2019;364:l689. PMID 30867144.
- Owen PJ, Miller CT, Mundell NL, et al. Which specific modes of exercise training are most effective for treating low back pain? Network meta-analysis. Br J Sports Med. 2020;54(21):1279-1287. PMID 31666220.
- Saragiotto BT, Maher CG, Yamato TP, et al. Motor control exercise for chronic non-specific low-back pain. Cochrane Database Syst Rev. 2016;1(1):CD012004. PMID 26742533.
- National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE Guideline NG59. London: NICE; 2016, last updated 29 July 2026. www.nice.org.uk/guidance/ng59.
- Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Eur Spine J. 2018;27(1):60-75. PMID 28429142.
- Saragiotto BT, Abdel Shaheed C, Overton M, Hayden JA, Hartvigsen J, Pinto RZ. Recent highlights in low back pain research, Part II: Prevention and management. J Physiother. 2026;72(2):106-115. PMID 41933950.
- Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE). Lancet. 2023;401(10391):1866-1877. PMID 37146623.
- Henschke N, Maher CG, Ostelo RW, de Vet HC, Macaskill P, Irwig L. Red flags to screen for malignancy in patients with low-back pain. Cochrane Database Syst Rev. 2013;(2):CD008686. PMID 23450586.
- Hancock M, Smith A, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): 3-year follow-up of a randomised, controlled trial. Lancet Rheumatol. 2025;7(11):e789-e798. PMID 40780241.
- Nijs J, Lahousse A, Kapreli E, et al. Nociplastic Pain Criteria or Recognition of Central Sensitization? J Clin Med. 2021;10(15):3203. PMID 34361986.
- de Zoete A, Innocenti T, Petrozzi MJ, et al. Spinal manipulative therapy for adults with chronic low back pain. Cochrane Database Syst Rev. 2026;1(1):CD008112. PMID 41494147.
How do you apply these recommendations concretely in your practice?
Applying evidence in clinical practice is the bridge between science and care. It is not limited to applying techniques, but encompasses clinical reasoning, interprofessional collaboration and rigorous evaluation of outcomes. 🧐
When, and to which other health professionals, should you refer?
One of the core skills of the physiotherapist, particularly in direct access, is the ability to identify situations that are beyond their scope of practice or that require further assessment.
The first level of vigilance concerns the red flags already described in detail. The Downie 2013 review (BMJ) and Premkumar 2018 (JBJS) recall their limits: an isolated flag has low diagnostic accuracy, but their combination and longitudinal analysis strengthen their predictive value.¹,²
The indications for prompt referral to the general practitioner or specialist :
- Suspected serious condition : history of cancer + unexplained weight loss, fever + immunosuppression, progressive neurological signs, suspected cauda equina (surgical emergency).1,2
- Suspected spondyloarthritis (age < 40, morning stiffness > 30 min, night waking in the second half of the night, HLA-B27 history): referral to the rheumatologist.
- Suspected severe radiculopathy with progressive motor deficit: specialist assessment (neurologist or rheumatologist), sometimes targeted imaging.
- No improvement after 4-6 weeks of appropriate management: systematic reassessment of red flags and referral.
🧠 Beyond serious conditions, referral is justified by the presence of complex psychosocial factors (yellow flags) : high levels of catastrophising (PCS > 30), kinesiophobia (TSK > 40), severe depression / anxiety.³ Identification through validated questionnaires (PCS, TSK, PHQ-9 / GAD-7) justifies collaboration with a psychologist specialising in pain, or with a psychiatrist.
🤝 Interprofessional collaboration is the keystone. For particular profiles:
- Occupational physician : workplace adjustments, gradual return to work, fitness-for-work assessment.
- Nutritionist / dietitian : if overweight or obesity is an aggravating factor.
- Psychologist specialising in pain : for patients with severe yellow flags, particularly in disabling chronic low back pain (the RESTORE 2023 trial demonstrated the value of an approach that integrates the psychological dimension).⁴
- Rheumatologist / spinal surgeon : failure of prolonged conservative treatment, severe radiculopathy, suspected spondyloarthritis.
Effective, structured communication (clear reports, shared follow-up of PROMs) is essential to continuity of care.
How do you measure outcomes and overcome barriers to implementation?
📊 The use of patient-reported outcome measures (PROMs) is a strong recommendation of international guidelines.5,6 These validated tools make it possible to quantify pain, function, quality of life and psychological impact, and to support shared decision-making.
📋 Validated PROMs for non-specific low back pain: the clinician's toolkit
Recommended minimum selection + MCID (minimal clinically important difference)
| PROM | Domain | Scale | Approx. MCID | Clinical use |
|---|---|---|---|---|
| NPRS (Numeric Pain Rating Scale) | Pain | 0-10 | ≈ 2 points | Every session, quick follow-up |
| RMDQ (Roland-Morris) | Disability related to low back pain | 0-24 | ≈ 5 points | Pivotal measure in RCTs (RESTORE) |
| ODI (Oswestry Disability Index) | Functional disability | 0-100 % | ≈ 10 points | Long-term follow-up, surgery |
| STarT Back Tool | Stratification of chronicity risk | 0-9 | - | Initial, guides matched care |
| FABQ (Fear-Avoidance Beliefs Q) | Fear-avoidance beliefs | 0-96 | - | Yellow flags, work / activity |
| PCS (Pain Catastrophizing Scale) | Catastrophising | 0-52 | - | Yellow flags, referral decision |
| TSK (Tampa Scale Kinesiophobia) | Fear of movement | 17-68 | - | Before return to sport |
| PSEQ (Pain Self-Efficacy) | Self-efficacy | 0-60 | - | CFT therapeutic target |
🚧 Barriers to implementation : implementation reviews identify several recurring barriers:⁵
- Lack of time in consultations to provide education, assess yellow flags and administer PROMs.
- Lack of skills to search for / appraise the literature and adapt it to the patient.
- Lack of organisational support and inertia of the reimbursement system (which often favours technical procedures over education).
- Residual clinical beliefs about the “biomedical model” (looking for the lesion, prescribing imaging, rest).
- Patient expectations shaped by social representations (“my vertebrae are out of place”) and historical over-medicalisation.
Implementation levers :
- Technological integration : practice management software with automated PROMs (sent before the session, trajectory tracking).
- Targeted continuing education on critical appraisal, biopsychosocial reasoning and communication. Short courses on EBP have shown their effectiveness.
- Practice culture : “journal club” meetings, peer mentoring, valuing the scientific approach.
- Synthesis : rely on the guidelines (NICE NG59, APTA 2021, Stochkendahl 2018) and recent reviews (Saragiotto J Physiother 2026 Part I & II) so as not to reinvent the wheel.9,10
Critique and controversy: beyond the guidelines
The rigid application of recommendations raises important questions.
⚖️ The “red flag paradox” : looking for them is a professional ethical obligation, but excessive focus on them can generate a nocebo effect (needless anxiety, a cascade of costly and sometimes iatrogenic tests). Competence lies not in ticking off a list, but in interpreting within an overall clinical context.1,2,7,8
📈 The gap between data and action on PROMs : many clinicians collect the scores but struggle to use them concretely to adjust treatment. The risk is turning a dialogue tool into an administrative formality. The challenge: for a PROM score to trigger specific clinical actions.5,6
🌍 The generalisability of RCTs to everyday practice remains a persistent controversy. RCTs recruit homogeneous populations; the “average” patient in practice is often more complex (comorbidities, particular psychosocial context). Applying a recommendation without adapting it to the individual is a mistake. True expertise lies in the ability to contextualise high-level evidence for a unique patient.
- The watch for red flags is essential but must be put in context: their combination and longitudinal follow-up are more informative than an isolated flag.1,2,7,8
- The PROMs (NPRS, RMDQ, ODI, STarT Back, PCS, TSK) are powerful tools when their results are actively used to adjust treatment and support shared decision-making.5,6
- Applying recommendations derived from RCTs must go hand in hand with adaptation to the context and particularities of each patient.
- Evidence-based practice rests on the balance between scientific rigour, clinical experience and patient values.
Bibliography
- Downie A, Williams CM, Henschke N, et al. Red flags to screen for malignancy and fracture in patients with low back pain: systematic review. BMJ. 2013;347:f7095. PMID 24335669.
- Premkumar A, Godfrey W, Gottschalk MB, Boden SD. Red Flags for Low Back Pain Are Not Always Really Red: A Prospective Evaluation of the Clinical Utility of Commonly Used Screening Questions for Low Back Pain. J Bone Joint Surg Am. 2018;100(5):368-374. PMID 29509613.
- Wertli MM, Rasmussen-Barr E, Weiser S, Bachmann LM, Brunner F. The role of fear avoidance beliefs as a prognostic factor for outcome in patients with nonspecific low back pain: a systematic review. Spine J. 2014;14(5):816-836.e4. PMID 24412032.
- Kent P, Haines T, O'Sullivan P, et al. Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE). Lancet. 2023;401(10391):1866-1877. PMID 37146623.
- George SZ, Fritz JM, Silfies SP, et al. Interventions for the Management of Acute and Chronic Low Back Pain: Revision 2021. J Orthop Sports Phys Ther. 2021;51(11):CPG1-CPG60. PMID 34719942.
- Foster NE, Anema JR, Cherkin D, et al. Prevention and treatment of low back pain: evidence, challenges, and promising directions. Lancet. 2018;391(10137):2368-2383. PMID 29573872.
- Verhagen AP, Downie A, Maher CG, Koes BW. Most red flags for malignancy in low back pain guidelines lack empirical support: a systematic review. Pain. 2017;158(10):1860-1868. PMID 28708761.
- Henschke N, Maher CG, Ostelo RW, de Vet HC, Macaskill P, Irwig L. Red flags to screen for malignancy in patients with low-back pain. Cochrane Database Syst Rev. 2013;(2):CD008686. PMID 23450586.
- National Institute for Health and Care Excellence (NICE). Low back pain and sciatica in over 16s: assessment and management. NICE Guideline NG59. London: NICE; 2016, last updated 29 July 2026. www.nice.org.uk/guidance/ng59.
- Pinto RZ, Kongsted A, Silva S, Hayden JA, Downie A, Saragiotto BT. Recent highlights in low back pain research, Part I: Diagnosis and Prognosis. J Physiother. 2026;72(1):23-32. PMID 41423384.
- Saragiotto BT, Abdel Shaheed C, Overton M, Hayden JA, Hartvigsen J, Pinto RZ. Recent highlights in low back pain research, Part II: Prevention and management. J Physiother. 2026;72(2):106-115. PMID 41933950.
- Stochkendahl MJ, Kjaer P, Hartvigsen J, et al. National Clinical Guidelines for non-surgical treatment of patients with recent onset low back pain or lumbar radiculopathy. Eur Spine J. 2018;27(1):60-75. PMID 28429142.
And after this read?
This article is part of a collection of evidence-based clinical syntheses. A question, a comment, a correction to suggest? Contact us directly through the WhatsApp button at the bottom right of the screen.





















